<DOC>
	<DOCNO>NCT01416194</DOCNO>
	<brief_summary>This observational cohort study conduct characterize select adverse event interest among patient population osteoporosis prescribe bazedoxifene , raloxifene , bisphosphonate usual clinical care outside randomize clinical trial setting . The study compare rate select clinical event among three treatment group .</brief_summary>
	<brief_title>Bazedoxifene Post Approval Safety Study ( PASS ) European Union ( EU )</brief_title>
	<detailed_description>All woman database meet inclusion criterion include study without statistical sampling .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Bazedoxifene</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<mesh_term>Raloxifene Hydrochloride</mesh_term>
	<criteria>Female At least one prescription bazedoxifene , raloxifene , bisphosphonate study inclusion period ( index prescription ) ; A recoded diagnosis code osteoporosis within 60 day prior index prescription date ; Age &gt; =45 date index prescription ; At least 6months followup data electronic medical record system prior date index prescription There exclusion criterion . All woman database meet inclusion criterion study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Osteoporosis</keyword>
</DOC>